Parkinson Disease Panel

Concurrent analysis of multiple genes associated with parkinsonism, characterized by resting tremor, muscle rigidity, bradykinesia, and/or postural instability.

NY Approved

Test Overview

Clinical Utility

  • Molecular confirmation of a clinical diagnosis
  • Identification of at-risk family members
  • Assist with treatment/ management decisions
  • Recurrence risk assessment

Test Details

Genes

AFG3L2, ATP13A2, ATP6AP2, C19orf12, CHCHD2, COASY, CP, CYP27A1, DCTN1, DNAJC5, DNAJC6, FBXO7, FTL, GBA, GCH1, LRRK2, MAPT, NPC1, NPC2, NUS1, PANK2, PARK7, PDGFB, PDGFRB, PINK1, PLA2G6, POLG, PRKN, PRKRA, PTS, RAB39B, SLC20A2, SLC30A10, SLC6A3, SMPD1, SNCA, SYNJ1, TH, TWNK, VPS13A, VPS35, WDR45, XPR1, ZFYVE26

Conditions

  • Atypical parkinsonism
  • Bradykinesia
  • Dopa-responsive parkinsonism
  • Movement Disorder
  • Parkinson Disease
  • Parkinsonism
  • Progressive Supranuclear Palsy (PSP)
  • Tremors

Lab Method

  • Capillary Sequencing
  • Deletion/Duplication Analysis
  • Next-Gen Sequencing

Ordering Information

Test Code: T401
CPT Codes*: 81404x1, 81405x2, 81406x2, 81408x1, 81479x3
ABN Required: No
Turnaround Time**: 4 weeks
Preferred Specimen: 2-5 mL Blood - Lavender Top Tube
Alternative Specimen: Buccal Swabs

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

**Turnaround times are estimates and begin once the sample(s) begin processing at the GeneDx lab and could be extended in situations outside GeneDx’s control.

Resources

Test Documents

Billing

Targeted Variant Testing

FAQs